Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO
This article was originally published in Pharmaceutical Approvals Monthly
With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology
You may also be interested in...
Novartis Institute for Biomedical Research's six-year-old mechanism-based research model is cranking out targeted cancer therapeutics, with three new molecules headed for the clinic by the end of 2008
Novartis halts Phase III study of the mTOR inhibitor early after everolimus shows better progression-free survival than placebo.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.